Oral Mucositis Therapeutics Pipeline Analysis

Oral Mucositis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: June 2017
Report Code: LS11024
Available Format:
Pages: 93

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Pipeline Overview

Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.

Some of the symptoms associated with oral mucositis are open sores or bleeding, pain, redness or swelling, white patches, dry mouth, diarrhea, nausea, blood in mouth, thicker saliva in the mouth and difficulty in talking or swallowing. Oral mucositis can be treated by using antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses and mucosal coating agents.



Oral Mucositis Therapeutics Pipeline Analysis

Drug manufacturing companies are constantly in the quest to find better and new treatment strategies with potential targets such as glucocorticoid receptor and superoxide dismutase which can also prove to be effective in oral mucositis treatment. The U.S. Food and Drug Administration (USFDA) has granted various designations including orphan drug and fast track status to many drugs which are driving the growth of the pipeline.

Pipeline Analysis

As of May 2017, the oral mucositis pipeline comprises approximately 18 active drug candidates in different stages of development.

Competitive Landscape

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry